Journal of Travel Medicine, Journal Year: 2024, Volume and Issue: unknown
Published: Aug. 29, 2024
We present a case of coinfection with dengue and parainfluenza viruses, that has not been described in the literature to date. This emphasizes fever after travel is always caused by single disease. Appropriate research on sources infection control measures should be implemented.
Language: Английский
EClinicalMedicine, Journal Year: 2024, Volume and Issue: 78, P. 102943 - 102943
Published: Nov. 19, 2024
Language: Английский
Citations
4
Vaccines, Journal Year: 2025, Volume and Issue: 13(5), P. 483 - 483
Published: April 29, 2025
Dengue has emerged as a significant global health threat. Despite decades of research, only two dengue vaccines—CYD-TDV (Dengvaxia) and TAK-003 (Qdenga)—have been licensed to date, with limited implementation. This paper explores outlines strategies for integrating vaccines into routine immunization programs, particularly in high-burden regions. TAK-003, tetravalent live-attenuated vaccine, demonstrated 61% efficacy against virologically confirmed 84% hospitalizations endemic settings. However, concerns remain about vaccine-enhanced disease, among seronegative individuals exposed DENV3 DENV4. WHO recommends targeted introduction high-transmission settings without pre-vaccination screening, while ongoing post-introduction studies will further clarify long-term safety efficacy. Effective vaccine rollout requires multi-pronged approach, including school-based immunization, integration adolescent services, strong community engagement. Decision-making should be guided by National Immunization Technical Advisory Groups (NITAGs), local epidemiological data, cost-effectiveness assessments. While future vaccines, mRNA virus-like particle candidates, are under development, optimizing the use currently available is crucial reducing dengue’s public impact. Given continued rise cases, immediate action—combining vaccination vector control—is essential prevent morbidity mortality.
Language: Английский
Citations
0
Schweizerische medizinische Wochenschrift, Journal Year: 2024, Volume and Issue: 154(9), P. 3858 - 3858
Published: Sept. 19, 2024
Dengue fever, endemic to most tropical and subtropical countries, is a major cause of illness in travellers, but severe dengue, hospitalisation death are considered rare this population. Two vaccines against dengue Dengvaxia® Qdenga®, available. While there no recommendation for the use Qdenga® has been licensed travellers many European countries since December 2022, recently (29 July 2024) Switzerland by Swissmedic. The Swiss Expert Committee Travel Medicine (ECTM), having assessed available data on vaccine, issues following recommendations: (1) Vaccination fever virus with not recommended persons previous infection. (2) may be aged 6 years older who have evidence infection, defined as (a) laboratory-confirmed infection (PCR, antigen or seroconversion) (b) compatible history positive IgG serological test AND expected exposure region significant transmission. medicine advisors should provide clear information accessible language complexity risk/benefit evaluation their travellers.
Language: Английский
Citations
3
Journal of Travel Medicine, Journal Year: 2024, Volume and Issue: unknown
Published: Aug. 29, 2024
We present a case of coinfection with dengue and parainfluenza viruses, that has not been described in the literature to date. This emphasizes fever after travel is always caused by single disease. Appropriate research on sources infection control measures should be implemented.
Language: Английский
Citations
0